文献速递甲状腺疾病

甲状腺吸收剂量与Graves病放射性碘治疗反应关系的系统综述与荟萃分析

A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
PubMed 文献 · Thyroid · 2021-01-01

该系统综述与荟萃分析纳入15项研究共2303例Graves病患者,评估甲状腺吸收剂量与放射性碘治疗后转归的关系。每增加10 Gy,非甲状腺功能亢进(OR=1.11,95%CI 1.08-1.14)和甲状腺功能减退(OR=1.09,95%CI 1.06-1.12)的几率显著增加;吸收剂量在120-180 Gy范围内甲状腺功能正常率更高(OR=2.50,95%CI 1.17-5.35,p=0.018),128 Gy时甲状腺功能正常反应最大为38%。

要点

  • 甲状腺吸收剂量每增加10 Gy,非甲亢及甲减转归几率均显著增加。
  • 吸收剂量120-180 Gy范围内甲状腺功能正常率高于范围外(OR=2.50)。
  • 128 Gy时甲状腺功能正常反应最大,为38%。

核心结论

  • 甲状腺吸收剂量与Graves病放射性碘治疗后非甲亢及甲减转归存在显著关联。
  • 吸收剂量120-180 Gy范围内甲状腺功能正常率更高,128 Gy时最大为38%。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Web of Science、OVID MEDLINE和Embase截至2020年2月13日的文献。
  • 共纳入15项研究,包含2303例Graves病患者。
  • 采用随机效应荟萃分析合并比例,通过荟萃回归评估吸收剂量对转归的影响。
  • 研究注册于PROSPERO(CRD42020175010)。

主要发现

  • 每增加10 Gy,非甲亢转归OR=1.11(95%CI 1.08-1.14),甲减转归OR=1.09(95%CI 1.06-1.12)。
  • 吸收剂量120-180 Gy范围内甲状腺功能正常率高于范围外(n=1172,OR=2.50,95%CI 1.17-5.35,p=0.018)。
  • 128 Gy时甲状腺功能正常反应最大为38%。

临床怎么用

  • 所呈现的吸收剂量-反应关系可促进Graves病放射性碘治疗的个体化治疗计划。

局限性

  • 需要进一步研究以确定患者特异性协变量如何影响个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome. Methods: A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010). Results: A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR] = 1.11 [95% confidence interval {CI} 1.08-1.14] and OR = 1.09 [CI 1.06-1.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120-180 Gy when compared with outside this range (n = 1172, OR = 2.50 [CI 1.17-5.35], p = 0.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy. Conclusions: The presented radiation absorbed dose-response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Taprogge J, Gape PMD, Carnegie-Peake L, et al. A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease. Thyroid. 2021. PMID: 34598656. doi:10.1089/thy.2021.0302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。